RIPK1: A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Target Name: RIPK1

NCBI ID: G8737

RIPK1

RIPK1: A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Introduction

RIPK1 (Receptor (TNFRSF)-interacting serine-threonine kinase 1) is a protein that plays a crucial role in the regulation of cell signaling pathways, including the T cell signaling pathway. RIPK1 has been implicated in the development and progression of various neurodegenerative diseases , making it an attractive drug target and biomarker for the treatment of such diseases. In this article, we will discuss the structure, function, and potential therapeutic applications of RIPK1, as well as its potential as a drug target and biomarker in neurodegenerative diseases.

Structure and Function

RIPK1 is a 21-kDa protein that is composed of 220 amino acid residues. It has a molecular weight of 21 kDa and a calculated pI of 5.5. RIPK1 is a serine-threonine kinase, which means that it consists of a catalytic site at the interface between its amino acid residues and a substrate site at the amino acid residue that interacts with the kinase.

The RIPK1 kinase domain consists of a catalytic cycle that consists of a G12A32 loop, a G22A64 loop, and a G22A86 loop. The catalytic cycle is the central part of RIPK1's structure and is responsible for the kinetic catalytic activity of the protein. The G12A32 loop is the first critical structural element in the catalytic cycle, as it forms the interface between the protein's amino acid residues and the substrate. The G22A64 loop is the second critical element in the catalytic cycle and is responsible for the regulation of the activity of the structural enzyme. The G22A86 loop is the third critical structural element in the catalytic cycle and is responsible for the regulation of the stability of the enzyme.

The RIPK1 substrate site is located at the amino acid residue Glu122, which is the Glu274 residue in the human protein. Glu122 is a key substrate for the protein rutin, a bioactive flavonoid found in various fruits and vegetables. Rutin has Anti-platelet aggregation, improvement of microcirculation, anti-tumor, anti-inflammatory and other pharmacological effects. By inhibiting RIPK1 activity, the risk of neuronal death and neurodegenerative diseases can be reduced.

Potential Therapeutic Applications

RIPK1 has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases due to its involvement in the regulation of neurotransmitter signaling pathways, including the T cell signaling pathway. The inhibition of RIPK1 activity has been shown to protect neuronal survival and slowing the progression of neurodegenerative diseases.

One of the major challenges in the development of neurodegenerative disease treatments is the difficulty of targeting the RIPK1 enzyme due to its high stability and the presence of multiple isoforms in the brain. This has led to the development of small interfering RNA (siRNA) technology as a tool to knockdown RIPK1 in the brain. SiRNA-mediated knockdown of RIPK1 has been shown to protect neuronal survival and improve the development of neurodegenerative diseases.

In addition to its potential use as a drug target, RIPK1 has also been identified as a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. The levels of RIPK1 in brain tissue can be used as a marker for the diagnosis of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Conclusion

RIPK1 is a protein that plays a crucial role in the regulation of cell signaling pathways, including the T cell signaling pathway. Its inhibition has been shown to protect neuronal survival and slow down the development of neurodegenerative diseases. as a drug target

Protein Name: Receptor Interacting Serine/threonine Kinase 1

Functions: Serine-threonine kinase which is a key regulator of TNF-mediated apoptosis, necroptosis and inflammatory pathways (PubMed:32657447, PubMed:31827280, PubMed:31827281, PubMed:17703191, PubMed:24144979). Exhibits kinase activity-dependent functions that regulate cell death and kinase-independent scaffold functions regulating inflammatory signaling and cell survival (PubMed:11101870, PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Has kinase-independent scaffold functions: upon binding of TNF to TNFR1, RIPK1 is recruited to the TNF-R1 signaling complex (TNF-RSC also known as complex I) where it acts as a scaffold protein promoting cell survival, in part, by activating the canonical NF-kappa-B pathway (By similarity). Kinase activity is essential to regulate necroptosis and apoptosis, two parallel forms of cell death: upon activation of its protein kinase activity, regulates assembly of two death-inducing complexes, namely complex IIa (RIPK1-FADD-CASP8), which drives apoptosis, and the complex IIb (RIPK1-RIPK3-MLKL), which drives necroptosis (By similarity). RIPK1 is required to limit CASP8-dependent TNFR1-induced apoptosis (By similarity). In normal conditions, RIPK1 acts as an inhibitor of RIPK3-dependent necroptosis, a process mediated by RIPK3 component of complex IIb, which catalyzes phosphorylation of MLKL upon induction by ZBP1 (PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Inhibits RIPK3-mediated necroptosis via FADD-mediated recruitment of CASP8, which cleaves RIPK1 and limits TNF-induced necroptosis (PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Required to inhibit apoptosis and necroptosis during embryonic development: acts by preventing the interaction of TRADD with FADD thereby limiting aberrant activation of CASP8 (By similarity). In addition to apoptosis and necroptosis, also involved in inflammatory response by promoting transcriptional production of pro-inflammatory cytokines, such as interleukin-6 (IL6) (PubMed:31827280, PubMed:31827281). Phosphorylates RIPK3: RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation (PubMed:19524513). Phosphorylates DAB2IP at 'Ser-728' in a TNF-alpha-dependent manner, and thereby activates the MAP3K5-JNK apoptotic cascade (PubMed:17389591, PubMed:15310755). Required for ZBP1-induced NF-kappa-B activation in response to DNA damage (By similarity)

The "RIPK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RIPK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets